Acurx Pharmaceuticals (ACXP) Set to Announce Earnings on Monday

Acurx Pharmaceuticals (NASDAQ:ACXPGet Rating) will announce its earnings results before the market opens on Monday, November 14th. Investors interested in listening to the company’s conference call can do so using this link.

Acurx Pharmaceuticals (NASDAQ:ACXPGet Rating) last released its quarterly earnings results on Monday, August 15th. The company reported ($0.26) EPS for the quarter.

Acurx Pharmaceuticals Price Performance

NASDAQ ACXP opened at $2.91 on Friday. The firm has a market cap of $33.63 million, a PE ratio of -2.40 and a beta of -0.84. Acurx Pharmaceuticals has a one year low of $2.33 and a one year high of $5.50. The stock’s 50 day simple moving average is $3.29 and its 200 day simple moving average is $3.43.

Analyst Ratings Changes

Separately, Alliance Global Partners started coverage on Acurx Pharmaceuticals in a research report on Thursday, October 20th. They set a “buy” rating on the stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. BlackRock Inc. raised its position in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXPGet Rating) by 149.8% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 16,699 shares of the company’s stock after buying an additional 10,014 shares during the period. BlackRock Inc. owned about 0.16% of Acurx Pharmaceuticals worth $55,000 as of its most recent filing with the SEC. 3.03% of the stock is owned by hedge funds and other institutional investors.

Acurx Pharmaceuticals Company Profile

(Get Rating)

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections.

Further Reading

Earnings History for Acurx Pharmaceuticals (NASDAQ:ACXP)

Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with's FREE daily email newsletter.